EBS:NYE-Emergent Biosolutions Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 10.27

Change

+0.71 (+7.43)%

Market Cap

USD 1.16B

Volume

1.23M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Emergent BioSolutions Inc is a specialty biopharmaceutical company It develops, manufactures, and delivers a portfolio of medical countermeasures for government agencies in the areas of biological and chemical threats and emerging infectious diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.37B
HLN Haleon plc

N/A

USD 44.13B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 42.24B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 13.11B
CTLT Catalent Inc

N/A

USD 11.52B
ELAN Elanco Animal Health

N/A

USD 5.75B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.59B
BHC Bausch Health Companies Inc

N/A

USD 2.75B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M

ETFs Containing EBS

BNKE:LSE Lyxor EURO STOXX Banks UC.. 3.04 % 0.00 %

N/A

USD 0.30M
BINV 2023 ETF Series Trust - B.. 2.15 % 0.00 %

N/A

USD 0.14B
EMUM:SW iShares MSCI EMU Mid Cap .. 1.93 % 0.00 %

N/A

USD 0.14B
FEUZ First Trust Eurozone Alph.. 1.35 % 0.80 %

N/A

USD 0.02B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

N/A

N/A
LDEU:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

N/A

USD 0.04B
FEP First Trust Europe AlphaD.. 1.01 % 0.80 %

N/A

USD 0.18B
EUMD:LSE iShares MSCI Europe Mid C.. 0.00 % 0.00 %

N/A

USD 0.27B
FEUZ:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.06B
FEUD:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.01B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
IS3H:XETRA iShares MSCI EMU Mid Cap .. 0.00 % 0.00 %

N/A

USD 0.13B
FTEU:LSE First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.06B
FTGE:XETRA First Trust Eurozone Alph.. 0.00 % 0.00 %

N/A

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.43% 93% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.43% 93% A 98% N/A
Trailing 12 Months  
Capital Gain 335.17% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 335.17% 100% F 100% F
Trailing 5 Years  
Capital Gain -81.07% 21% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.07% 21% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -20.90% 7% C- 2% F
Dividend Return -20.90% 7% C- 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 95.83% 20% F 9% A-
Risk Adjusted Return -21.81% 20% F 10% F
Market Capitalization 1.16B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector